Realm Therapeutics applies to trial novel allergic conjunctivitis therapy in the USA

Realm Therapeutics (AIM: RLM) has submitted for approval to launch a Phase II trial for PR013, a candidate treatment for allergic conjunctivitis.

The UK-based biopharmaceutical firm, formerly known as PuriCore, aims to test the drug for patients aged 10 years and older in a multi-center, double-blind, randomized trial with approximately 90 subjects.

The planned trial will use a modified Conjunctival Allergen Challenge Model for assessment, the framework used by the majority of Food and Drug Administraton approved treatments in this area.

The company says that PR013, a high-concentration formulation of hypochlorous acid, has shown promise in in vitro studies at inhibiting both histaminergic and non-histaminergic itching associated with the disease. Antihistamines focus on the former only.

This advantage means that the company aims to address the unmet needs of approximately 30% of patients who do not respond to the current standard of care.